About Company
Altesa BioSciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing antiviral treatments for respiratory viruses and other global viral threats.
Founded in 2022 and headquartered in Atlanta, Georgia, Altesa BioSciences focuses on creating innovative antiviral drugs targeting common respiratory viruses such as rhinovirus and parainfluenza, as well as vector-borne viral diseases like Dengue and Zika. The company has established a partnership with Drug Innovation Ventures at Emory (DRIVE), leveraging their expertise and resources to advance its drug development pipeline. Altesa's lead candidate, Vapendavir, is currently in Phase 2 clinical trials aimed at treating viral infections in vulnerable populations, including those with chronic obstructive pulmonary disease (COPD).